News

Fungal Meningitis Outbreak Exposes Lack of Regulatory Oversight


 

The 23 states that received the implicated lots of medication are California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Maryland, Michigan, Minnesota, North Carolina, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, and West Virginia.

All reports of complaints or problems associated with these products should be made at the MedWatch website, the FDA’s voluntary reporting program, or by calling 800-FDA-1088.

Pages

Recommended Reading

Prescription Drug Monitoring Programs Still Cumbersome
MDedge Neurology
Topical Pain Relievers: FDA Issues Burn Warning
MDedge Neurology
Novel Occipital Neuralgia Treatment Addresses C-1 Nerve
MDedge Neurology
Depression can be migraine's tipping point
MDedge Neurology
Chronic Musculoskeletal Pain Travels with Chronic Daily Headache
MDedge Neurology
Yoga, Tai Chi Underused in Rheumatic Pain Management
MDedge Neurology
Botox for Chronic Migraine Brings Cost Savings
MDedge Neurology
Botox May Greatly Reduce Migraine Chronicity
MDedge Neurology
Fungal Meningitis Cases, Deaths Continue to Rise
MDedge Neurology
Weighing Botox's Migraine Benefits Against Costs
MDedge Neurology